KalVista Pharmaceuticals (KALV) Competitors $13.34 +0.13 (+0.98%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. CRNX, IMVT, ALVO, MOR, OGN, NAMS, RXRX, GMTX, RARE, and MIRMShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Alvotech (ALVO), MorphoSys (MOR), Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Crinetics Pharmaceuticals Immunovant Alvotech MorphoSys Organon & Co. NewAmsterdam Pharma Recursion Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Mirum Pharmaceuticals KalVista Pharmaceuticals (NASDAQ:KALV) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do insiders and institutionals have more ownership in KALV or CRNX? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer KALV or CRNX? In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 3 mentions for KalVista Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.88 beat KalVista Pharmaceuticals' score of 0.25 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, KALV or CRNX? KalVista Pharmaceuticals has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Do analysts rate KALV or CRNX? KalVista Pharmaceuticals currently has a consensus target price of $26.29, indicating a potential upside of 97.04%. Crinetics Pharmaceuticals has a consensus target price of $69.50, indicating a potential upside of 150.47%. Given Crinetics Pharmaceuticals' higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable valuation & earnings, KALV or CRNX? KalVista Pharmaceuticals has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.62Crinetics Pharmaceuticals$760K3,418.44-$298.41M-$3.82-7.26 Is KALV or CRNX more profitable? Crinetics Pharmaceuticals' return on equity of -30.95% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -134.07% -82.65% Crinetics Pharmaceuticals N/A -30.95%-28.12% SummaryCrinetics Pharmaceuticals beats KalVista Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$667.23M$2.51B$5.54B$9.48BDividend YieldN/A1.80%4.74%4.13%P/E Ratio-3.629.0828.9423.96Price / SalesN/A549.97412.94176.66Price / CashN/A22.2824.4827.20Price / Book6.954.908.475.70Net Income-$183.44M$31.61M$3.25B$265.26M7 Day Performance-1.69%-4.25%-1.22%-2.41%1 Month Performance12.10%3.92%7.82%6.73%1 Year Performance1.29%-1.37%27.10%20.03% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.8078 of 5 stars$13.34+1.0%$26.29+97.0%+0.3%$667.23MN/A-3.62100CRNXCrinetics Pharmaceuticals3.3126 of 5 stars$30.30-2.2%$69.50+129.4%-44.1%$2.90B$1.04M0.00210Positive NewsUpcoming EarningsIMVTImmunovant1.613 of 5 stars$16.76-1.1%$36.40+117.2%-43.6%$2.90BN/A0.00120Upcoming EarningsALVOAlvotech3.8677 of 5 stars$9.81+2.1%$14.00+42.7%-23.8%$2.90B$491.98M16.571,032Positive NewsGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.8714 of 5 stars$9.96-2.4%$18.00+80.7%-53.3%$2.65B$6.40B2.824,000Upcoming EarningsNAMSNewAmsterdam Pharma3.3425 of 5 stars$23.42-0.8%$41.30+76.3%+25.0%$2.65B$45.56M-12.464Positive NewsUpcoming EarningsRXRXRecursion Pharmaceuticals1.3797 of 5 stars$6.31-2.8%$7.00+10.9%-19.1%$2.64B$58.84M0.00400Upcoming EarningsGap DownGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+37.7%$2.63BN/A-60.6130RAREUltragenyx Pharmaceutical4.4857 of 5 stars$27.61+1.0%$82.57+199.1%-43.6%$2.58B$560.23M-4.701,294MIRMMirum Pharmaceuticals3.9601 of 5 stars$51.49-0.7%$65.50+27.2%+32.1%$2.57B$336.89M0.00140Upcoming Earnings Related Companies and Tools Related Companies CRNX Alternatives IMVT Alternatives ALVO Alternatives MOR Alternatives OGN Alternatives NAMS Alternatives RXRX Alternatives GMTX Alternatives RARE Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
